Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by yea
… highlight the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential … the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Top-line data now expected to be … to, statements regarding sepofarsen (QR-110) and the clinical development and the therapeutic potential thereof, … the cost, timing and results of preclinical studies and clinical trials and other development activities by us and …